The appearance of the SARS-CoV-2 virus initiated many studies on the effects of the virus on the human body. So far, its negative influence on the functioning of many morphological and physiological units, including the nervous system, has been demonstrated. Consequently, research has been conducted on the changes that SARS-CoV-2 may cause in the cholinergic system. The aim of this study is to review the latest research from the years 2020/2021 regarding disorders in the cholinergic system caused by the SARS-CoV-2 virus. As a result of the research, it was found that the presence of the COVID-19 virus disrupts the activity of the cholinergic system, for example, causing the development of myasthenia gravis or a change in acetylcholine activity. The SARS-CoV-2 spike protein has a sequence similar to neurotoxins, capable of binding nicotinic acetylcholine receptors (nAChR). This may be proof that SARS-CoV-2 can bind nAChR. Nicotine and caffeine have similar structures to antiviral drugs, capable of binding angiotensin-converting enzyme 2 (ACE 2) epitopes that are recognized by SARS-CoV-2, with the potential to inhibit the formation of the ACE 2/SARS-CoV-2 complex. The blocking is enhanced when nicotine and caffeine are used together with antiviral drugs. This is proof that nAChR agonists can be used along with antiviral drugs in COVID-19 therapy. As a result, it is possible to develop COVID-19 therapies that use these compounds to reduce cytokine production. Another promising therapy is non-invasive stimulation of the vagus nerve, which soothes the body’s cytokine storm. Research on the influence of COVID-19 on the cholinergic system is an area that should continue to be developed as there is a need for further research. It can be firmly stated that COVID-19 causes a dysregulation of the cholinergic system, which leads to a need for further research, because there are many promising therapies that will prevent the SARS-CoV-2 virus from binding to the nicotinic receptor. There is a need for further research, both in vitro and in vivo. It should be noted that in the functioning of the cholinergic system and its connection with the activity of the COVID-19 virus, there might be many promising dependencies and solutions.

This study was undertaken to determine the redox balance in the developing brain after exposure to acrylamide (ACR), a potent neurotoxin. The studies were performed using an in ovo chick embryo model. The antioxidant enzymes SOD, GPx, CAT, and reduced glutathione (GSH) were used as indicators of the redox balance. Eggs were injected with ACR doses of 40 mg kg egg mass (2.4 mg egg) on embryonic day 17 (E17). The activity of the antioxidant enzymes and the concentration of GSH were measured at E17, E18, and E19 in the medulla oblongata, cerebrum, cerebellum, and optic lobe. The results indicated a significant decrease in the GSH concentrations in the optic lobe (E19, E20) and cerebrum (E20) of embryos exposed to ACR. The activities of SOD and GPx were significantly increased in the majority of the examined structures after injection of ACR. CAT activity was completely inhibited in the brains of the embryos exposed to ACR compared to that in the brains of the control embryos. Thus, we concluded that ACR exerts a significant influence on the redox balance in the developing brain by impacting the activity of antioxidant enzymes and the levels of GSH.

No abstract

No abstract